Montpellier, France

Stephane Delbecq

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, Institut De Recherche Pour Le Developpement (Ird), Universitè De Montpellier. Active years: 2018.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Stephane Delbecq

Introduction

Stephane Delbecq is a notable inventor based in Montpellier, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating parasitic diseases. His work is characterized by a focus on innovative solutions that address critical health challenges.

Latest Patents

Delbecq holds a patent for "N-hydroxybenzamides as HDAC inhibitors for the treatment of parasitic diseases." This patent describes compounds of a specific formula, wherein n is 0, 1, or 2; X is a defined group, and Ar is a benzyl substituted at the meta position by a Cto Calkoxy group. These compounds are designed for treating, preventing, or inhibiting parasitic diseases, such as toxoplasmosis, in subjects. The patent also presents methods for preparing these compounds, showcasing Delbecq's innovative approach to addressing health issues.

Career Highlights

Throughout his career, Delbecq has been associated with prestigious institutions such as Université de Montpellier and the Centre National de la Recherche Scientifique. His work in these organizations has allowed him to contribute to significant advancements in research and development in the field of parasitology.

Collaborations

Delbecq has collaborated with esteemed colleagues, including Corinne Loeuillet and Jean-Francois Alexandre Guichou. These partnerships have further enriched his research and have led to impactful findings in the realm of medicinal chemistry.

Conclusion

Stephane Delbecq's innovative work in developing HDAC inhibitors represents a significant advancement in the treatment of parasitic diseases. His contributions to science and medicine continue to inspire future research and innovation in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…